Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial von Powles, Thomas, Oudard, Stephane, Vulsteke, Christof, Fléchon, Aude, Yu, Evan Y, Imai, Kentaro, Homet Moreno, Blanca, Alva, Ajjai, Lazzaro, Mauricio Fernandez, Gatica, Gabriela, Van Aelst, Filip, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Soares, Joao Paulo Holanda, Cheng, Susanna, Leal, Jose Luis, Ibanez, Carolina, Laguerre, Brigitte, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Gravis, Gwenaelle, Reichardt, Peter, Herden, Jan, Pfister, David, Niegisch, Guenter, Boegemann, Martin, Gakis, Georgios, Neisius, Andreas, Thomas, Christian, Kosa, Judit Erzsebet, Bodoky, Gyorgy, Geczi, Lajos, Frank, Stephen Jay, Kejzman, Daniel, Rosenbaum, Eli, Rouvinov, Keren, Arai, Gaku, Takayama, Tatsuya, Fujimoto, Kiyohide, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Takano, Toshimi, Joraku, Akira, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Beerepoot, Laurens, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Karlov, Petr Alexandrovich, Cohen, Graham Lawrence, Ruff, Paul, Lee, Nari, Rodriguez-Vida, Alejo, Grande, Enrique, Munoz Langa, Jose, Montesa Pino, Alvaro, Su, Wen-Pin, Chang, Yen-Hwa, Huang, Yi-Hsiu, Srimuninnimit, Vichien, Abali, Huseyin, Sendur, Mehmet Ali Nahit, Ozguroglu, Mustafa, Ozdogan, Mustafa, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Schlegel, Peter, Mamtani, Ronac, Wallace, James, Suh, Jason Jung-Gon, Burgess, Earle, Wong, John, Chaudhry, Arvind, Thomas, Christian A, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Joshi, Monika, Bolemon, Britt H, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Courtright, Jay G, Doshi, Gurjyot, Sartor, Oliver Alton, Mannuel, Heather D, Alva, Ajjai, Charles, Anthony, Ades, Steven, Yu, Evan, Fleming, Mark

Volltext

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enza... von Vogelzang, Nicholas J., Levin, Richard, Rezazadeh, Arash, Park, Chandler H., Bolemon, Britt Haley, Gabrail, Nashat Y., Malik, Zulfiqar A., Nordquist, Luke T., Ross, Ashley, Zhang, Phoebe, Zhou, Karl

Volltext

Randomized multicenter open-label trial of GT0918 (proxalutamide) in patients with mCRPC that progressed on abiraterone or enzalutamide von Vogelzang, Nicholas J., Rezazadeh Kalebasty, Arash, Levin, Richard, Malik, Zulfiqar A., Ross, Ashley, Bolemon, Britt Haley, Gabrail, Nashat Y., Zhang, Phoebe, Zhou, Karl

Volltext

Over Expression of MN1 Confers Resistance to Chemotherapy In Vitro and In Vivo von Pardee, Timothy, Mascenik, Teresa, Bolemon, Britt H., Cook, Guerry J

Volltext

Optimal timing of systemic therapy in resectable colorectal liver metastases von Ihemelandu, Chukwuemeka, Levine, Edward A, Aklilu, Mebea, Yacoub, George, Howerton, Russell, Bolemon, Britt, Graham, Matthew, Russell, Greg, Shen, Perry

Volltext